Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Trenton T Ross"'
Autor:
Justin D. Crane, Ornella Barrandon, Bryan Faherty, Matt Gorgoglione, Collin Crowley, Jeff Morin, Trenton T. Ross, Jackson Shimkonis, Dongmei Li, Dinesh Hirenallur-Shanthappa, Magalie Boucher, Youngwook Ahn, Michelle F. Clasquin
Publikováno v:
Journal of Lipid Research, Vol 65, Iss 10, Pp 100634- (2024)
Human genetic studies show that loss of function mutations in 17-Beta hydroxysteroid dehydrogenase (HSD17β13) are associated with protection from non-alcoholic steatohepatitis (NASH). As a result, therapies that reduce HSD17β13 are being pursued fo
Externí odkaz:
https://doaj.org/article/f9c9afd4a56244a1a6af56e1047fd7fb
Autor:
Derek M Erion, Amanda Lapworth, Paul A Amor, Guoyun Bai, Nicholas B Vera, Ronald W Clark, Qingyun Yan, Yimin Zhu, Trenton T Ross, Julie Purkal, Matthew Gorgoglione, Guodong Zhang, Vinicius Bonato, Levenia Baker, Nicole Barucci, Theresa D'Aquila, Alan Robertson, Robert J Aiello, Jiangli Yan, Jeff Trimmer, Timothy P Rolph, Jeffrey A Pfefferkorn
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e97139 (2014)
Hyperglycemia resulting from type 2 diabetes mellitus (T2DM) is the main cause of diabetic complications such as retinopathy and neuropathy. A reduction in hyperglycemia has been shown to prevent these associated complications supporting the importan
Externí odkaz:
https://doaj.org/article/646e9e91d00f42f6a75e558c5e50e7cf
Autor:
Trenton T. Ross, Collin Crowley, Kenneth L. Kelly, Anthony Rinaldi, David A. Beebe, Matthew P. Lech, Robert V. Martinez, Santos Carvajal-Gonzalez, Magalie Boucher, Dinesh Hirenallur-Shanthappa, Jeffrey Morin, Alan C. Opsahl, Sarah R. Vargas, Kendra K. Bence, Jeffrey A. Pfefferkorn, William P. Esler
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 10, Iss 4, Pp 829-851 (2020)
Background & Aims: Disordered metabolism, steatosis, hepatic inflammation, and fibrosis contribute to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase (ACC) catalyzes the first committed step in de novo lipogenesis (DNL
Externí odkaz:
https://doaj.org/article/beb0f489c5c840ed83b968a320f69c68
Autor:
Jemy A. Gutierrez, Wei Liu, Sylvie Perez, Gang Xing, Gabriele Sonnenberg, Kou Kou, Matt Blatnik, Richard Allen, Yan Weng, Nicholas B. Vera, Kristin Chidsey, Arthur Bergman, Veena Somayaji, Collin Crowley, Michelle F. Clasquin, Anu Nigam, Melissa A. Fulham, Derek M. Erion, Trenton T. Ross, William P. Esler, Thomas V. Magee, Jeffrey A. Pfefferkorn, Kendra K. Bence, Morris J. Birnbaum, Gregory J. Tesz
Publikováno v:
Molecular Metabolism, Vol 48, Iss , Pp 101196- (2021)
Objective: Recent studies suggest that excess dietary fructose contributes to metabolic dysfunction by promoting insulin resistance, de novo lipogenesis (DNL), and hepatic steatosis, thereby increasing the risk of obesity, type 2 diabetes (T2D), non-
Externí odkaz:
https://doaj.org/article/83d51c2650cb4492a69b4c32dbb702cc
Autor:
Kentaro Futatsugi, Shawn Cabral, Daniel W. Kung, Kim Huard, Esther Lee, Markus Boehm, Jonathan Bauman, Ronald W. Clark, Steven B. Coffey, Collin Crowley, Anne-Marie Dechert-Schmitt, Matthew S. Dowling, Robert Dullea, James R. Gosset, Amit S. Kalgutkar, Kou Kou, Qifang Li, Yajing Lian, Paula M. Loria, Allyn T. Londregan, Mark Niosi, Christine Orozco, John C. Pettersen, Jeffrey A. Pfefferkorn, Jana Polivkova, Trenton T. Ross, Raman Sharma, Ingrid A. Stock, Gregory Tesz, Hanna Wisniewska, Bryan Goodwin, David A. Price
Publikováno v:
Journal of medicinal chemistry. 65(22)
Discovery efforts leading to the identification of ervogastat (PF-06865571), a systemically acting diacylglycerol acyltransferase (DGAT2) inhibitor that has advanced into clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with
Autor:
Albert M. Kim, Neeta B. Amin, Arthur Bergman, Roberto A. Calle, Theresa Tuthill, Kou Kou, Sudeepta Aggarwal, Naresh Aggarwal, Collin Crowley, Anthony Rinaldi, Santos Carvajal-Gonzalez, Veena Somayaji, Kendra K. Bence, Jessica Mancuso, Trenton T. Ross, Magalie Boucher, William P. Esler, Robert Dullea, Jeffrey A. Pfefferkorn, Małgorzata Inglot, Greg Tesz
Publikováno v:
Nature Medicine. 27:1836-1848
Alterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, no pharmacological agents are currently approved in the United States or the European Union for the treatment of NAFLD. Two pa
Autor:
William S. Nowland, Steven W. Kumpf, Trenton T. Ross, Christopher J. Bowman, Gregg D. Cappon, Donald S Stedman, Scott D Davenport, William P. Esler, Christine Stethem, Natasha R. Catlin, Elise M. Lewis, Sarah N. Campion
Publikováno v:
Toxicological Sciences. 179:183-194
Acetyl-CoA carboxylase (ACC) is an enzyme within the de novo lipogenesis (DNL) pathway and plays a role in regulating lipid metabolism. Pharmacologic ACC inhibition has been an area of interest for multiple potential indications including oncology, a
Autor:
David A. Beebe, Gregg D. Cappon, Michelle Clasquin, Marc K. Hellerstein, Norimitsu Shirai, William J. Reagan, Zhongyuan Sun, Katherine Hales, Gabriele E. Sonnenberg, Jeffrey A. Pfefferkorn, Theodore J. Schmahai, Nicholas B. Vera, Marcy Matthews, Trenton T. Ross, Clare Buckeridge, Enida Ziso Qejvanaj, Kenneth L. Kelly, Shoh Asano, Santos Carvajal-Gonzalez, William P. Esler, Paul A. Amor, Kelvin W. Li, Arthur Bergman
Publikováno v:
Nature Metabolism. 2:1163-1178
Acetyl-CoA carboxylase (ACC) catalyses the first step of de novo lipogenesis (DNL). Pharmacologic inhibition of ACC has been of interest for therapeutic intervention in a wide range of diseases. We demonstrate here that ACC and DNL are essential for
Autor:
Shawn D. Doran, Jana Polivkova, James A. Southers, Scott W. Bagley, Kim Huard, Dilinie P. Fernando, Manthena V.S. Varma, David A. Beebe, David J. Edmonds, Robert L. Dow, Benjamin A. Thuma, Collin Crowley, William P. Esler, Trenton T. Ross, David A. Tess, Mark Niosi, Amit S. Kalgutkar, Jeffrey A. Pfefferkorn, Norimitsu Shirai, David A. Griffith, Shawn Cabral, Andrew H. Smith, Gregg D. Cappon, Vincent Mascitti, Matthew S. Dowling, Andre Shavnya, David Price, Ayman El-Kattan, Aaron C. Smith, Yi-an Bi, Spiros Liras, Xiaojing Helen Yang, Cathy Préville
Publikováno v:
Journal of Medicinal Chemistry. 63:10879-10896
Preclinical and clinical data suggest that acetyl-CoA carboxylase (ACC) inhibitors have the potential to rebalance disordered lipid metabolism, leading to improvements in nonalcoholic steatohepatitis (NASH). Consistent with these observations, first-
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
Autor:
Magalie Boucher, William P. Esler, Santos Carvajal-Gonzalez, David A. Beebe, Alan C. Opsahl, Trenton T. Ross, Jeffrey A. Pfefferkorn, Sarah R. Vargas, Anthony Rinaldi, Matthew P. Lech, Collin Crowley, Kendra K. Bence, Jeffrey Morin, Kenneth L. Kelly, Robert V. Martinez, Dinesh Hirenallur-Shanthappa
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 10, Iss 4, Pp 829-851 (2020)
Background & Aims Disordered metabolism, steatosis, hepatic inflammation, and fibrosis contribute to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase (ACC) catalyzes the first committed step in de novo lipogenesis (DNL)